Promising Trends: The Role of SGLT2 Inhibitors in Type 2 Diabetes Treatment and their Cardiovascular Impacts
DOI:
https://doi.org/10.36557/2674-8169.2024v6n2p821-829Keywords:
SGLT2 inhibitorsAbstract
This study reviewed the role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes and their cardiovascular impacts. Through the analysis of clinical studies, including those conducted with empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin, a significant reduction in the risk of adverse cardiovascular events was observed in patients treated with these medications. Additionally, SGLT2 inhibitors were associated with additional benefits, such as reducing the progression of renal disease and hospitalization for heart failure. However, further research is needed to fully understand the mechanisms of action of these medications and their potential long-term adverse effects. In summary, SGLT2 inhibitors represent an important therapeutic option in the management of type 2 diabetes, offering additional cardiovascular and renal benefits beyond glycemic control.
Downloads
References
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., ... & Zwiener, I. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128.
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., ... & Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644-657.
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., ... & Bhatt, D. L. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(4), 347-357.
McMurray, J. J., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., ... & Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial Committees and Investigators. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995-2008.
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., ... & Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants with Vascular Disease (VERTIS CV) Trial Investigators. (2020). Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New England Journal of Medicine, 383(15), 1425-1435.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 José Lucas Moura Vasconcelos, Antônia de Carvalho Pereira Pinto , Antonio Elcio Santos Silva , Anthonielly Leinat Lima , Camila Metelo Duarte , Carlos Eduardo do Carmo Almeida , César de Brito Parra Batista , Eduarda Medeiros Simsen, Geovana Pirassol Roque , Isabela Olivo Pires , João Pedro Azevedo Druszcz , João Victor Sola Barreto Marcelino, João Victor Sola Barreto Marcelino , Julia Borges Barbero, Laisse Oliveira Barbosa de Melo , Lucas Henrique Matias Dias Pereira , Raí Araújo Dourado Ferreira , Rafael Leituga de Carvalho Cavalcante, Ranielly Mendes Amorim, Rebeka Raquel Feliciano Queiroz, Stephane Izabor de Oliveira Costa , Valentine Ferlin , Victória Persigili , Wilson Cazarim Neto
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
